[HTML][HTML] Afatinib in EGFR TKI-Naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: a pooled analysis of three phase …
A Passaro, F de Marinis, HY Tu, KK Laktionov… - Frontiers in …, 2021 - frontiersin.org
… Dose reductions were permitted for adverse events (AEs). Efficacy endpoints included … be
more effective in prolonging PFS in older patients compared with younger patients (27, 28). We …
more effective in prolonging PFS in older patients compared with younger patients (27, 28). We …
Phase III clinical trial for the combination of erlotinib plus ramucirumab compared with osimertinib in previously untreated advanced or recurrent non–small cell lung …
N Haratake, H Hayashi, M Shimokawa, Y Nakano… - Clinical lung cancer, 2022 - Elsevier
… (OS) compared with gefitinib or erlotinib in patients with the … the efficacy of the combination
of erlotinib plus ramucirumab in … Adverse events are recorded on the basis of the National …
of erlotinib plus ramucirumab in … Adverse events are recorded on the basis of the National …
Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
S Wang, J Li - OncoTargets and therapy, 2019 - Taylor & Francis
… paronychia the most common adverse events (AEs) reported in … can be reduced without
reducing its effectiveness. Data … in patients treated with afatinib compared with erlotinib/gefitinib (…
reducing its effectiveness. Data … in patients treated with afatinib compared with erlotinib/gefitinib (…
Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
Z Zhang, K Zeng, S Zhao, Y Zhao… - Therapeutic …, 2019 - journals.sagepub.com
… evidence to compare the efficacy and toxicity among the regimens. … outcomes means high
efficacy and low adverse effects. … differences among gefitinib, erlotinib, or icotinib in terms of …
efficacy and low adverse effects. … differences among gefitinib, erlotinib, or icotinib in terms of …
Phase I/II study of capmatinib plus erlotinib in patients with MET-positive non–small-cell lung cancer
CE McCoach, A Yu, DR Gandara, JW Riess… - JCO precision …, 2021 - ascopubs.org
… The most frequent adverse effects were anorexia (33%), nausea (… plus erlotinib would be
safe and show efficacy in patients with EGFR… Finally, we acknowledge that differences in testing …
safe and show efficacy in patients with EGFR… Finally, we acknowledge that differences in testing …
Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study
TH Kim, JH Choi, MS Ahn, HW Lee, SY Kang, YW Choi… - BMC cancer, 2024 - Springer
… ) compared to first-generation EGFR-TKIs (gefitinib, erlotinib) [10… has demonstrated an OS
benefit compared to gefitinib [20]. … ≥ 3 adverse events resulting in negative effects on patients’ …
benefit compared to gefitinib [20]. … ≥ 3 adverse events resulting in negative effects on patients’ …
Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non-small-cell lung cancer: A meta analysis
M Yi, T He, K Wang, Y Wei - Clinics, 2023 - SciELO Brasil
… comparing the efficacy and safety of gefitinib in combination with chemotherapy versus gefitinib
alone in patients with … reversible EGFR TKIs including gefitinib and erlotinib, the second-…
alone in patients with … reversible EGFR TKIs including gefitinib and erlotinib, the second-…
[HTML][HTML] RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe …
SP Aix, S Novello, EB Garon, K Nakagawa… - Cancer Treatment and …, 2021 - Elsevier
… compared to EGFR alone increases anti-tumor efficacy. The … plus erlotinib (RAM + ERL) over
placebo plus erlotinib (PBO + ERL… were treatment-emergent adverse events (TEAEs). Dose …
placebo plus erlotinib (PBO + ERL… were treatment-emergent adverse events (TEAEs). Dose …
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial
M Riudavets, M Naigeon, M Texier, M Dorta, F Barlesi… - Lung Cancer, 2022 - Elsevier
… Here we provide the efficacy data from the entire cohort. … Dose-limiting toxicity (DLT) was
defined as any adverse event (… A post-hoc survival analysis was performed comparing patients …
defined as any adverse event (… A post-hoc survival analysis was performed comparing patients …
Gefitinib plus chemotherapy vs gefitinib alone in untreated EGFR-mutant non–small cell lung cancer in patients with brain metastases: the GAP BRAIN open-label …
X Hou, M Li, G Wu, W Feng, J Su, H Jiang… - JAMA Network …, 2023 - jamanetwork.com
… of adverse events were compared with the Fisher exact test … to compare the intracranial
efficacy and safety of gefitinib plus … of EGFR T790M mutation with erlotinib alone at progression. …
efficacy and safety of gefitinib plus … of EGFR T790M mutation with erlotinib alone at progression. …